Literature DB >> 7560318

Pulmonary zygomycosis: CT appearance.

D A Jamadar1, E A Kazerooni, B D Daly, C S White, B H Gross.   

Abstract

OBJECTIVE: We describe the CT appearance of pulmonary zygomycosis (mucormycosis), an opportunistic infection typically occurring in immunocompromised patients.
MATERIALS AND METHODS: Eight patients with pulmonary zygomycosis imaged with CT were reviewed, seven at initial diagnosis and one with a subsequent complication. The appearance, number, and location of pulmonary lesions and the presence of pleural effusions and extrapulmonary involvement were assessed. Rim enhancement, air bronchograms, the halo sign, air crescent sign, cavitation, and central low attenuation suggesting necrosis were recorded.
RESULTS: There were 14 nodules and 5 areas of mass-like or wedge-shaped consolidation. Pleural effusion was present in five patients, halo sign in three, central low attenuation in two, and cavitation in one. In the affected lobe 13 of 14 nodules and all consolidations were posterior. Of 19 lesions 16 (84%) were confined to the upper lobes, with 3 in the superior segment of a lower lobe. Endobronchial disease with lobar collapse was the only manifestation in one patient. Major complications were direct spinal invasion in one patient and multiple pulmonary artery pseudoaneurysms in another patient.
CONCLUSION: In the appropriate clinical circumstance, nodules or mass-like or wedge-shaped consolidation, especially posteriorly in the upper lobes of the lung, should suggest zygomycosis. Endobronchial zygomycosis is less common.

Entities:  

Mesh:

Year:  1995        PMID: 7560318     DOI: 10.1097/00004728-199509000-00008

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  10 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

2.  Pulmonary mucormycosis developed during acute myelogenous leukemia and successfully treated by surgical resection before blood stem cell transplantation.

Authors:  Kentaro Miura; Nobutaka Kobayashi; Ichiro Ito; Nozomu Uematsu; Toshimitsu Ueki; Yuta Nakano; Hikaru Kobayashi
Journal:  AME Case Rep       Date:  2019-12-27

Review 3.  Pulmonary vasculitis: diagnosis and endovascular therapy.

Authors:  Kiran Batra; Murthy Chamarthy; Rodrigo Caruso Chate; Kirk Jordan; Fernando Uliana Kay
Journal:  Cardiovasc Diagn Ther       Date:  2018-06

Review 4.  The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts.

Authors:  Sarah P Georgiadou; Nikolaos V Sipsas; Edith M Marom; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

Review 5.  CT Findings of COVID-19-associated Pulmonary Mucormycosis: A Case Series and Literature Review.

Authors:  Mandeep Garg; Nidhi Prabhakar; Valliappan Muthu; Shameema Farookh; Harsimran Kaur; Vikas Suri; Ritesh Agarwal
Journal:  Radiology       Date:  2021-08-31       Impact factor: 11.105

6.  Sequential morphological changes in follow-up CT of pulmonary mucormycosis.

Authors:  Ji Yung Choo; Chang Min Park; Hyun-Ju Lee; Chang Hyun Lee; Jin Mo Goo; Jung-Gi Im
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

7.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

8.  Pulmonary zygomycosis: A clinicopathological study.

Authors:  Sundaram Challa; Shantveer G Uppin; Megha S Uppin; Roshni T Paul; Aruna K Prayaga; Manmadha T Rao
Journal:  Lung India       Date:  2011-01

9.  The Role of Transbronchial Lung Biopsy in Diagnosing Pulmonary Mucormycosis in a Critical Care Unit.

Authors:  Yoonki Hong; Jinkyeong Park
Journal:  Korean J Crit Care Med       Date:  2017-05-31

Review 10.  Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.

Authors:  Ayushi Sharma; Anjana Goel
Journal:  Folia Microbiol (Praha)       Date:  2022-02-26       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.